Makary's exit creates new uncertainty at FDA

Source: Adriel Bettelheim

Adriel Bettelheim is a veteran journalist with coverage of government, politics, health care policy, telecommunications, science, and technology since 1994 at outlets like Congressional Quarterly's CQ Weekly, Politico, Bloomberg, and currently Axios as senior health care editor. He previously reported for the Denver Post and Syracuse Herald-Journal, and holds a degree from Case Western Reserve University. No fact-checking violations or major corrections are documented.

Source: Marty Makary

Marty Makary is a British-American surgeon and professor emeritus at Johns Hopkins University School of Medicine, renowned for pioneering laparoscopic Whipple and Frey’s procedures and leading the WHO Surgery Checklist. He authored influential books like *The Price We Pay* and *Blind Spots*, praised for exposing healthcare pricing issues. His 13-month FDA commissioner tenure (April 2025–May 2026) ended in resignation amid agency upheaval and political pressures.

Source: Axios

Axios, founded in 2016 by former Politico executives Jim VandeHei, Mike Allen, and Roy Schwartz, delivers brief articles under 300 words using bullet points and industry-specific newsletters, positioning itself as 'smart, efficient news worthy of your time, attention, and trust.' It grew to 500 employees by 2022 before its $525 million acquisition by Cox Enterprises on September 1, 2022. No fact-checking track record or third-party credibility ratings are provided in the sources.

unverified_claim

Quotes Sen. Dick Durbin (D-Ill.) as saying: 'I hope Dr. Makary will inspire others within the Trump administration to grow a spine and put the families of America ahead of blind loyalty to this president.'"

Presents a specific, inflammatory quote from a prominent Democrat praising Makary's independence, which shapes perception of bipartisan support; unverifiable quotes undermine credibility.

unverified_claim

Claims Trump wrote on Truth Social that Makary 'was a hard worker, who was respected by all, and will go on to have an outstanding career in medicine.'"

Alters perception of Trump's tone toward Makary; searches confirm Trump praised Makary and shared his resignation text, but exact phrasing unconfirmed.

Missing Context

HHS Secretary Robert F. Kennedy Jr. posted on X praising Makary: “Marty, you took on entrenched interests, challenged the status quo, and never lost sight of the American people we serve. You pushed forward critical reforms and helped advance our mission to Make America Healthy Again.”"

Provides key praise from a top Trump admin official (HHS Sec), balancing the article's emphasis on criticism and showing support from MAHA/Trump inner circle, which counters the 'done in by management' narrative.

Framing

States: 'various health interests... were calling for a reset. It was a sign of how much surprise policy moves, organizational upheaval and political interference have come to characterize an agency once known for predictability and evidence-based decision-making.' Presents 'political interference' as established fact rather than contested claim."

Implies Trump-era FDA lacks predictability/evidence-base without evidence, framing prior admins positively and current negatively; neutral would attribute to critics.

Source Credibility

Quotes Raymond James analyst Chris Meekins twice on Makary's failures and challenges without disclosing his firm's pharma client ties or potential bias toward deregulation."

Analyst from investment firm likely favors pro-business FDA; omitting context risks laundering industry-preferred view as neutral analysis.

Omission

Omits praise from HHS Secretary Robert F. Kennedy Jr., who posted on X: “Marty, you took on entrenched interests, challenged the status quo... helped advance our mission to Make America Healthy Again.”"

Downplays support from top Trump admin official, reinforcing narrative of universal criticism and failure rather than mixed reception with achievements."

Framing

Leads with "Makary's departure... may remove one of the Trump administration's lightning rods for controversy" and describes "organizational upheaval and political jockeying that marked much of his 13-month tenure."

Frames Makary and Trump FDA as chaotic from the start, priming negative perception; neutral lead would note resignation amid mixed reviews."

Missing Context

Makary's tenure included efforts to reshape vaccine policy and transform diets, as noted in ABC News and his official FDA bio."

Article questions if successor will continue 'streamline clinical trials' but omits Makary's actual reforms like vaccine policy changes, altering view of his legacy from purely chaotic to partially achievement-oriented."

unverified_claim

Claims 'complaints from health care investors about unpredictable regulatory decisions that rejected some promising drugs.'"

Presents specific investor backlash as fact, contributing to narrative of Makary's failure; unverifiable details risk misleading on reasons for departure.

Framing

Describes FDA as 'once known for predictability and evidence-based decision-making,' implying Makary/Trump era deviated without evidence or comparison."

Nostalgic framing idealizes pre-Trump FDA, biasing toward view of current leadership as uniquely disruptive; neutral would note all admins face similar critiques.

Missing Context

FDA under Makary implemented over 20 reforms in one year, including accelerating biosimilars, reducing animal testing, revising COVID-19 vaccine framework, and launching new dietary guidelines."

Article questions if successor will continue streamlining but omits Makary's documented achievements, skewing legacy as purely chaotic rather than reform-oriented amid challenges.

Missing Context

No major right-leaning outlets like Fox News, NY Post, or Breitbart covered Makary's resignation prominently.

Suggests story not a major conservative flashpoint; omission allows left-leaning framing without counter-narratives emphasizing MAHA successes.